Editorial: Multi Target - Directed Ligands in the Treatment of Alzheimer's Disease.
Editorial: Multi Target - Directed Ligands in the Treatment of Alzheimer's Disease. Curr Alzheimer Res. 2019;16(9):771 Authors: Soukup O, Korabecny J PMID: 31729288 [PubMed - in process]
ConclusionsThis study provides information about Aβ plaque burden, tau tangle burden, and neurodegeneration in cognitively unimpaired persons at three levels of genetic risk for AD. Unimpaired APOE ϵ4 HMs can be studied before their 70s to evaluate the understanding of factors, processes, and interventions involved in the predisposition to and prevention of AD, and after their 70s, to discover factors, processes, and interventions involved in the resilience or resistance to and prevention of AD.
Conclusions: In conclusion, we identified the extensive landscape of altered genes and pathways in colorectal cancer liver metastasis, which will be useful to design clinical therapy for personalized medicine. PMID: 31814826 [PubMed]
MRI-guided low-intensity focused ultrasound (LIFU) can safely open the blood-brain barrier (BBB) and allow for targeted delivery of drugs in patients with Alzheimer's disease (AD), according to new preliminary research.Reuters Health Information
Publication date: Available online 9 December 2019Source: Progress in Lipid ResearchAuthor(s): M.I. McDermott, Y. Wang, M.J.O. Wakelam, V.A. BankaitisAbstractDespite being discovered over 60 years ago, the precise role of Phospholipase D (PLD) is still being elucidated. PLD enzymes catalyze the hydrolysis of the phosphodiester bond of glycerophospholipids producing phosphatidic acid and the free headgroup. PLD family members are found in organisms ranging from viruses, and bacteria to plants, and mammals, and they display a range of substrate specificities, are regulated by a diverse range of molecules, and have been imp...
This study provides an important strategy in learning the cellular processes that are highly associated with intracellular biothiol level.
AbstractChronic neuroinflammation is strongly associated with AD and altered peripheral and central levels of chemokines and cytokines have been frequently described in those with AD. Given the increasing evidence of ethnicity-related differences in AD, it was of interest to determine if those altered chemokine and cytokine levels are ethnicity-related. Because African Americans exhibit a higher incidence of AD and increased symptom severity, we explored chemokine and cytokine concentrations in post-mortem brain tissue from the BA21 region of African Americans and Caucasians with AD using multiplex assays. IL-1 β, MIG...
The BACE inhibitor lanabecestat and the antibiotic minocycline failed to slow cognitive decline in randomized controlled trials.Medscape Medical News
Condition: Mild Cognitive Impairment Interventions: Drug: T-817MA; Drug: Placebo Sponsor: FUJIFILM Toyama Chemical Co., Ltd. Recruiting
Irene Taylor Brodsky's doc reveals her deaf son's triumph and her deaf dad's Alzheimer's challenges ... "If you told my dad 50 years ago that there would be this tool that would allow him to hear, ...
In conclusion, DZSM capsules protected against cognitive defects of AD through scutellarin-mediated acceleration of Aβ aggregation into fibrils or protofibrils and reduction of soluble Aβ oligomers, thus suggesting potential clinical applications of DZSM capsules and scutellarin in the treatment of AD. PMID: 31810113 [PubMed - in process]